109 results found.
          
DePuy Synthes Reports 1Q17 Revenue
ORTHOWORLD estimates DePuy Synthes' 1Q17 orthopaedic revenue at US $2,269.7MM, +0.4% vs. 1Q16.
Company Revenue 2016
For these publicly-traded orthopaedic device companies, Exhibits 1 and 2 present 2016 orthopaedic revenue and growth. Exhibit 1 includes links to company's full-year revenue reporting, as well. ...
Top 5 Orthopaedic Players Post Revenue Growth
Combined, the top five largest players in orthopaedics posted 2016 revenue of US $28.6BB, up $671.7MM or +2.4% vs. ...
DePuy Synthes 2016 Revenue
DePuy Synthes posted 2016 orthopaedic revenue of US $9,003.5MM, +0.8% vs. 2015, with 4Q16 revenue of $2,302.8MM, -1.5%
Company Revenue 3Q16: A Final Look
By Julie A. Vetalice As we wrap up orthopaedic revenue for the latest reporting period, we observe that Stryker and Zimmer Biomet lead the largest orthopaedic companies in 3Q16 growth:
Anika Therapeutics Reports 3Q16 Orthobiologic Revenue
Anika Therapeutics posted 3Q16 orthobiologic revenue of US $22.4MM, +9.6% vs. 3Q15.
DePuy Synthes/JNJ Posts 3Q16 Revenue
DePuy Synthes posted 3Q16 orthopaedic revenue of US $2,251.0MM, +3.2% vs. 3Q15. (U.S. $1,343.0MM, +2.4%; ex-U.S. $90...
Company Revenue Update, 1H16
By Julie A. Vetalice We complete our coverage of 1H16 revenue in this issue. Stryker and Smith & Nephew lead the top five in growth, with 1H16 performance in the low-single-digits compared to 1H15. DePuy Synthes and Zimmer Biomet reported
DePuy Synthes/JNJ Posts 2Q16 Revenue
DePuy Synthes posted 2Q16 orthopaedic revenue of US $2,355MM, +1.1% vs. 2Q15. (U.S. $1,364MM, +3.3%; ex-U.S. $991MM,...
Anika Therapeutics Posts 1Q16 Revenue
Anika Therapeutics posted 1Q16 orthobiologic revenue of US $19.6MM, +63.5% vs. 1Q15, as-reported.
DePuy Synthes/JNJ Reports 1Q16 Revenue
DePuy Synthes posted 1Q16 orthopaedic revenue of US $2,341MM, +0.6% vs. 1Q15, as reported.
Company Revenue 2015: K2M
2015: $215.9MM, +16.9% CC (U.S. $155.3MM, +16.7%; ex-U.S. $60.7MM, +17.7% CC) 4Q15: $54.2MM, +10.7% CC ORTHOWORLD estimates 2015 segment revenue and as-reported growth as follows. Spine $211.5MM, +15.6% Orthobiologics $4.4MM, +18.6% ...
Anika Therapeutics Posts 4Q15/2015 Revenue
Anika Therapeutics posted 4Q15 orthobiologics revenue of US $21.5MM, +63% vs. 4Q14, and 2015 revenue of $73.2M...
Company Revenue 2015: Anika Therapeutics
2015: $73.2MM, +18% 4Q15: $21.5MM, +63% Received $5MM milestone revenue for reaching target MONOVISC U.S. end-user sales of $50MM Full-year combined U.S. viscosupplementation revenue +24%, with MONOVISC more than tripling Commenced 200-patient enr...
DePuy Synthes/JNJ Reports 4Q15 and 2015 Revenue
DePuy Synthes posted 2015 orthopaedic revenue of US $9,262MM, -4.3% as reported and +1.7% operational (excludes the effect of c...
Company Revenue 2015: DePuy Synthes/Johnson & Johnson
Download the March issue of ORTHOKNOW for a graphical presentation of 2015 company performance. 2015: $9,262MM, -4.3% +1.7% op...
Johnson & Johnson Announces Restructuring Actions in Medical Devices
Johnson & Johnson, parent company of DePuy Synthes, will undertake restructuring actions in its Medic...
DePuy Synthes/Johnson & Johnson Reports 3Q15 Revenue
DePuy Synthes reported 3Q15 orthopaedic revenue of US $2,181.0MM, -7% from 3Q14 on an as-reported basis and -0.7%
Company Revenue 2015: Tornier
2Q15: $83.2MM, +4.0% (U.S. $50.1MM, +2.6%; ex-U.S. $33.1MM, +5.7%) Total Extremities $71.7MM, +6.0% Upper $56.5MM, +11.9% Lower $11.9MM, -13.8% Sports Med/...
BARE BONES® - July 14, 2015
DePuy Synthes/Johnson & Johnson posted 2Q15 orthopaedic sales of US $2,330MM, +0.9% vs. 2Q14. (U.S. $1,321MM, +2.1%; ex-U.S. $1,009MM, -0.4%) (Global growth by segment: Hips +2%, Knees
BARE BONES® - April 14, 2015
DePuy Synthes/Johnson & Johnson posted 1Q15 orthopaedic sales of US $2,328MM, +2.1% vs. 1Q14. (U.S. $1,309MM, +1.3%; ex-U.S. $1,019MM, +2.9%) (Global growth by segment: Hips +3%, Knees...
2014 Revenue: Anika Therapeutics
4Q14 revenue: $13.2MM, -14% 2014 revenue: $61.9MM, +11% (MONOVISC +258%)   4Q revenues impacted by lack of unique CMS J-Code for MONOVISC for 8 months post-launch, DePuy Mitek inventory reset, temporary slowdown in ex-U.S. sales...
BARE BONES® - January 20, 2015
DePuy Synthes/Johnson & Johnson posted 4Q14 orthopaedic sales of US $2,441MM, +2.8% from 4Q13, and 2014 orthopaedic sales of $9,675MM, +2.9% from 2013. (2014 U.S. $5,197MM, +2.4%; ex-U.S.
2014 Revenue: DePuy Synthes/Johnson & Johnson
2014 revenue $9,675MM, +3% (U.S. $5,197MM, +2%; ex-U.S. $4,478MM, +4%) Hips +4% Knees +3% Trauma +5% Beginning to realize benefits of scale/breadth, strategic wins in key markets, from combined busin...
BARE BONES® - October 14, 2014
DePuy Synthes/Johnson & Johnson posted 3Q14 orthopaedic sales of US $2,344MM, +2.9% from 3Q13. (U.S. $1,272MM, +3.2%, ex-U.S. $1,072MM, +2.4%; Hips +4%: U.S. +4%, ex-U.S.
  • ORTHOWORLD INC.
  • 8401 Chagrin Road, Suite 18
  • Chagrin Falls, Ohio 44023 USA
  • Phone: 440.543.2101 • Fax: 440.543.2122
  • ©1992-2019 ORTHOWORLD
  • All Rights Reserved.
  • Site Managed By:
  • Open Professional Group